Últimas noticias sobre Danaher (NYSE:DHR) Bolsa

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.19% on an annualized basis producing an average annual return of 14.69%. Currently, Danaher has a market capitalization of $160.47 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $390.71 today based on a price of $223.16 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738269014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years

RBC Capital analyst Conor McNamara reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $299 to $277.

Reiteration

RBC Capital Reiterates Outperform on Danaher, Lowers Price Target to $277

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $268 to $258.

Baird Maintains Outperform on Danaher, Lowers Price Target to $258

Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported weaker-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/dhr/earnings">earnings on Wednesday</a>.
The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.
The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.
Rainer M. Blair, President and Chief Executive Officer, stated, "Good execution by our team also drove solid cash flow and operating margin expansion."
Danaher said it expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.
Danaher shares fell 9.7% to close at $223.73 on Wednesday.
These analysts made changes to their price targets on Danaher following earnings announcement.
<ul>
<li>Barclays analyst Luke Sergott maintained Danaher with an Equal-Weight and lowered the price target from $275 to $240.</li>
<li>Wells Fargo analyst Brandon Couillard maintained Danaher with an Equal-Weight and cut the price target from $280 to $240.</li>
</ul>
Considering buying DHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png" alt="" class="wp-image-758143" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261.png 1120w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>

Earnings

Markets

Danaher Analysts Cut Their Forecasts After Downbeat Earnings

Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $280 to $240.

Wells Fargo Maintains Equal-Weight on Danaher, Lowers Price Target to $240

Barclays analyst Luke Sergott maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $275 to $240.

Barclays Maintains Equal-Weight on Danaher, Lowers Price Target to $240

Analysts' ratings for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $275.0, a high estimate of $290.00, and a low estimate of $260.00. Experiencing a 6.78% decline, the current average is now lower than the previous average price target of $295.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738188044_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Danaher among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$260.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$265.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Danaher. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Danaher's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Danaher's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Danaher analyst ratings.</a>
<h2>Get to Know Danaher Better</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Danaher: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Danaher's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.09%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Danaher's ROA stands out, surpassing industry averages. With an impressive ROA of 1.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.34.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Danaher Stock

Jefferies analyst Tycho Peterson maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $260.

Jefferies Maintains Buy on Danaher, Lowers Price Target to $260

Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision <a href="https://www.benzinga.com/topic/interest-rates">at 2 p.m. ET</a>.
The Fed is widely expected to keep interest rates unchanged at 4.25%-4.5%. Market participants remain highly focused on any signals from Fed Chair Jerome Powell regarding the path forward for rate cuts.
The December meeting delivered a shock to markets, with Powell adopting a more hawkish tone than anticipated, suggesting that interest rates have moved closer to a neutral zone.
This FOMC meeting is also the first since Donald Trump's administration took office, fueling speculation over whether Powell will address questions about the president's pledge to &#8220;lower interest rates immediately.&#8221;
Major equity indices are little changed, with tech stocks under slight pressure as Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 5%, weighing on the sector. Tech titans Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) will report earnings after the close, with investors awaiting management clarity over the DeepSeek AI competitive threat.
Among sectors, financial stocks — tracked by the Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) — hit fresh record highs, while communication services are on pace for their eighth consecutive session of gains.
The dollar and Treasury yields remain mostly flat ahead of the Fed's announcement. Commodities are mixed, with gold and oil down 0.4% and 0.9%, respectively, while silver and copper rise 1.2% and 1.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up 1% to $102,300, potentially snapping a four-session losing streak.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,901.37</td>
<td>0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,285.29</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,055.43</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,412.74</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012925&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% lower to $603.11.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;is flat at $448.62.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.2% lower to $520.88.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) is flat at $226.81.</li>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) is outperforming, up 0.8%; the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) is lagging, down 0.9%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) soared nearly 8% in reaction to stronger-than-expected quarterly results.</li>
<li>Other stocks reacting to company earnings include Starbucks Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>), up 6.7%, Chubb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), up 3%, F5 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), up 13%, ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) up 3.6%, Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), down 9%, The Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), up 1.4%, Automatic Data Processing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>), up 2.9%, General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>), down 3.2%, Norfolk Southern Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>), up 3.1%, MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>), down 3.9%, Nasdaq Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), up 0.9%, Hess Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>), up 0.6% and Teva Pharmaceuticals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), down 13.8%. </li>
<li>Major companies reporting earnings after the close other than Microsoft and Meta include Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) and Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>). </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43304027/deepseek-selloff-is-a-correction-not-start-of-sustained-bear-market-goldman-sachs">DeepSeek Selloff Is A Correction, Not Start Of &#8216;Sustained Bear Market&#8217;: Goldman Sachs</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Sector ETFs

Broad U.S. Equity ETFs

Federal Reserve

Movers

ETFs

$BTC

ASML

SPDR Dow Jones Industrial Average ETF Trust

FFIV

LRCX

MSCI

MSFT

NDAQ

NVDA

SBUX

TEVA

TMUS

TSLA

Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday?

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.4% on Wednesday.
Shares of Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/MANH/earnings">soft FY25 guidance.</a>
Manhattan Associates said it sees FY2025 adjusted earnings of $4.45 to $4.55 per share, versus market estimates of $4.91 per share. The company expects sales of $1.060 billion to 1.070 billion, versus projections of $1.14 billion.
Manhattan Associates shares dipped 23.4% to $225.92 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) shares dipped 21.5% to $1.4999 in pre-market trading.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) fell 21% to $13.30 in pre-market trading following worse-than-expected reported fourth-quarter EPS results.</li>
<li>Avnet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) shares fell 7.4% to $48.56 in pre-market trading following weak quarterly earnings.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) fell 6.4% to $20.16 in pre-market trading following fourth-quarter reported financial results.</li>
<li>Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) dipped 6.3% to $35.51 in pre-market trading. Victoria&#8217;s Secret announced that Chief Financial and Administrative Officer Timothy Johnson is retiring in June 2025 and Scott Sekella has been appointed Chief Financial Officer.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) fell 6.2% to $232.54 in pre-market trading after the company reported quarterly adjusted EPS below estimates..</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) fell 6% to $5.47 in pre-market trading. American Axle &amp; Manufacturing and Dowlais announced plans to merge in a $1.44 billion cash-and-stock deal.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43263799/wall-streets-most-accurate-analysts-spotlight-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

GSAT

MANH

VSCO

Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) shares are trading lower in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43296936/danaher-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">premarket session on Wednesday.</a>
The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.
The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.
The company exited the quarter with cash and equivalents worth $2.078 billion, and inventories worth $2.330 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43295848/nasdaq-jumps-2-after-nvidia-other-tech-stocks-bounce-back-from-deepseek-hit-greed-index-remains-in-fear-zone" rel="noreferrer noopener">Nasdaq Jumps 2% After Nvidia, Other Tech Stocks Bounce Back From DeepSeek Hit: Greed Index Remains In &#8216;Fear&#8217; Zone</a>
Danaher&#8217;s long-term debt as of quarter end totaled $15.50 billion. Operating cash flow was&nbsp;$2.0 billion in the fourth quarter&nbsp;and non-GAAP free cash flow was&nbsp;$1.5 billion.
Rainer M. Blair, President and Chief Executive Officer, stated, &#8220;Good execution by our team also drove solid cash flow and operating margin expansion.&#8221;
Outlook: Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter.
However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.
Blair continued, &#8220;Looking ahead, we believe Danaher is better positioned than at any point in our 40-year history&#8221;.&nbsp;
&#8220;The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash flow.&#8221;
Price Action: DHR shares are trading lower by 5.48% to $234.26 premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43266082/jim-cramer-coterra-energy-is-the-cheapest-natural-gas-company-recommends-buying-this-financial-stock" target="_blank" rel="noreferrer noopener">Jim Cramer Recommends Buying ‘Fabulous' BlackRock, Calls Coterra Energy The ‘Cheapest' Natural Gas Company</a></li>
</ul>
Photo via Shutterstock.

Guidance

General

Danaher Q4: EPS Miss Expectations Amid Diagnostics Segment Lag

WIIM

Danaher shares are trading lower after the company reported Q4 adjusted EPS below estimates.

Danaher Anticipates Non-GAAP Core Revenue To Decline Low-single Digits YoY In Q1 And To Increase Approximately 3% YoY In FY25

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported quarterly earnings of $2.14 per share which missed the analyst consensus estimate of $2.16 by 0.93 percent. This is a 2.39 percent increase over earnings of $2.09 per share from the same period last year. The company reported quarterly sales of $6.54 billion which beat the analyst consensus estimate of $6.42 billion by 1.77 percent. This is a 2.08 percent increase over sales of $6.41 billion the same period last year.

Earnings Beats

Earnings Misses

Danaher Q4 2024 Adj EPS $2.14 Misses $2.16 Estimate, Sales $6.54B Beat $6.42B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) is likely to report quarterly earnings at $1.97 per share on revenue of $1.28 billion. 
• Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) is projected to report quarterly earnings at $0.82 per share on revenue of $385.34 million. 
• Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) is likely to report quarterly earnings at $0.96 per share on revenue of $3.63 billion. 
• Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) is projected to report quarterly earnings at $0.70 per share on revenue of $4.12 billion. 
• Wabash National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $412.92 million. 
• Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) is likely to report quarterly earnings at $0.63 per share on revenue of $6.20 billion. 
• Southside Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSI#NYSE">SBSI</a>) is projected to report quarterly earnings at $0.71 per share on revenue of $68.12 million. 
• MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) is estimated to report quarterly earnings at $3.96 per share on revenue of $747.63 million. 
• Hess Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESM#NYSE">HESM</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $388.90 million. 
• Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $311.88 million. 
• Central Pacific Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPF#NYSE">CPF</a>) is estimated to report quarterly earnings at $0.62 per share on revenue of $67.00 million. 
• Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) is likely to report quarterly earnings at $4.00 per share on revenue of $575.21 million. 
• Blue Foundry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFY#NASDAQ">BLFY</a>) is likely to report quarterly loss at $0.17 per share on revenue of $10.02 million. 
• Avnet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $5.56 billion. 
• Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $5.27 million. 
• Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) is likely to report quarterly earnings at $2.97 per share on revenue of $3.03 billion. 
• Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $278.05 million. 
• Group 1 Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) is estimated to report quarterly earnings at $9.09 per share on revenue of $5.21 billion. 
• Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $1.12 billion. 
• Silgan Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) is likely to report quarterly earnings at $0.83 per share on revenue of $1.40 billion. 
• VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $2.75 billion. 
• Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) is expected to report quarterly earnings at $1.50 per share on revenue of $3.05 billion. 
• Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $136.80 million. 
• Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) is expected to report quarterly earnings at $0.75 per share on revenue of $1.22 billion. 
• CGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIB#NYSE">GIB</a>) is likely to report quarterly earnings at $1.40 per share on revenue of $2.64 billion. 
• Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) is expected to report quarterly earnings at $1.33 per share on revenue of $303.21 million. 
• Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) is expected to report quarterly earnings at $3.56 per share on revenue of $18.76 billion. 
• General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) is expected to report quarterly earnings at $4.23 per share on revenue of $13.21 billion. 
• Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) is expected to report quarterly earnings at $2.21 per share on revenue of $1.08 billion. 
• T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) is projected to report quarterly earnings at $2.30 per share on revenue of $21.37 billion. 
• Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $3.76 billion. 
• Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) is expected to report quarterly earnings at $4.14 per share on revenue of $1.23 billion. 
• M/I Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHO#NYSE">MHO</a>) is likely to report quarterly earnings at $4.83 per share on revenue of $1.17 billion. 
• Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is projected to report quarterly earnings at $2.15 per share on revenue of $6.39 billion. 
• Scotts Miracle Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) is likely to report quarterly loss at $1.23 per share on revenue of $392.29 million. 
• Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) is expected to report quarterly earnings at $2.30 per share on revenue of $4.97 billion. 
• ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) is expected to report quarterly earnings at $6.71 per share on revenue of $9.02 billion. 
<h3>Companies Reporting After The Bell</h3>
• Whirlpool (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) is likely to report quarterly earnings at $4.31 per share on revenue of $4.23 billion. 
• Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) is estimated to report quarterly earnings at $0.58 per share on revenue of $2.91 billion. 
• John B Sanfilippo &amp; Son (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBSS#NASDAQ">JBSS</a>) is likely to report earnings for its second quarter. 
• Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) is projected to report quarterly loss at $1.00 per share on revenue of $179.89 million. 
• Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) is likely to report quarterly earnings at $0.56 per share on revenue of $1.39 billion. 
• Bassett Furniture Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSET#NASDAQ">BSET</a>) is projected to report quarterly loss at $0.01 per share on revenue of $82.97 million. 
• Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) is estimated to report quarterly earnings at $0.37 per share on revenue of $-21 million. 
• Tetra Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $1.10 billion. 
• Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is projected to report quarterly earnings at $0.76 per share on revenue of $27.12 billion. 
• Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is estimated to report quarterly earnings at $0.91 per share on revenue of $740.91 million. 
• Washington Trust Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WASH#NASDAQ">WASH</a>) is estimated to report quarterly earnings at $0.58 per share on revenue of $48.36 million. 
• Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is estimated to report quarterly earnings at $1.79 per share on revenue of $5.90 billion. 
• Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) is likely to report quarterly earnings at $1.10 per share on revenue of $1.57 billion. 
• Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) is projected to report quarterly earnings at $1.84 per share on revenue of $4.26 billion. 
• First Interstate BancSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) is projected to report quarterly earnings at $0.46 per share on revenue of $251.46 million. 
• Benchmark Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $660.00 million. 
• United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) is likely to report quarterly earnings at $11.71 per share on revenue of $3.94 billion. 
• Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) is estimated to report quarterly earnings at $1.34 per share on revenue of $1.20 billion. 
• Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $4.32 billion. 
• High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $99.08 million. 
• Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is expected to report quarterly earnings at $3.12 per share on revenue of $68.86 billion. 
• Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $994.31 million. 
• Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) is expected to report quarterly earnings at $1.07 per share on revenue of $994.61 million. 
• Annaly Capital Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>) is projected to report quarterly earnings at $0.66 per share on revenue of $1.26 billion. 
• Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $219.22 million. 
• Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $1.73 billion. 
• Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) is likely to report quarterly earnings at $9.19 per share on revenue of $4.47 billion. 
• Ethan Allen Interiors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) is likely to report quarterly earnings at $0.61 per share on revenue of $160.60 million. 
• Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) is estimated to report quarterly earnings at $2.01 per share on revenue of $1.27 billion. 
• ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) is projected to report quarterly earnings at $3.65 per share on revenue of $2.96 billion. 
• SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) is likely to report quarterly earnings at $1.20 per share on revenue of $555.43 million. 
• Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) is expected to report quarterly earnings at $1.05 per share on revenue of $346.15 million. 
• Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) is likely to report quarterly earnings at $1.04 per share on revenue of $2.51 billion. 
• Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is projected to report quarterly earnings at $6.73 per share on revenue of $46.98 billion. 
• Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) is expected to report quarterly earnings at $2.66 per share on revenue of $3.47 billion. 
• National Fuel Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFG#NYSE">NFG</a>) is estimated to report quarterly earnings at $1.53 per share on revenue of $615.17 million. 
• MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $90.00 million. 
• Brookline Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKL#NASDAQ">BRKL</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $90.68 million. 
• Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $3.96 billion. 
• IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) is likely to report quarterly earnings at $3.79 per share on revenue of $17.60 billion. 
• Bridgewater Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWB#NASDAQ">BWB</a>) is expected to report quarterly earnings at $0.24 per share on revenue of $27.65 million. 
• Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) is estimated to report quarterly earnings at $2.53 per share on revenue of $1.33 billion. 
• C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $4.43 billion. 
• Core Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $133.59 million. 
• Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $203.91 million. 
• Cimpress (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPR#NASDAQ">CMPR</a>) is projected to report quarterly earnings at $2.38 per share on revenue of $968.96 million. 
• Century Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCS#NYSE">CCS</a>) is projected to report quarterly earnings at $3.18 per share on revenue of $1.28 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLFY

BRKL

BSET

CALX

CHRW

CMPR

CODA

EXTR

FIBK

FLEX

HESM

HITI

HWKN

JBSS

LBRT

LEVI

LSTR

MEOH

MNRO

NAVI

OTIS

SBSI

SEIC

SIGI

SLGN

TTEK

VIRT

WASH

WOLF

Earnings Scheduled For January 29, 2025

Investors with a lot of money to spend have taken a bearish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 66%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $107,681, and 6 are calls, for a total amount of $369,760.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $247.5 and $280.0 for Danaher, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Danaher's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Danaher's substantial trades, within a strike price spectrum from $247.5 to $280.0 over the preceding 30 days.
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738080954_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$255.00</td>
<td>$113.1K</td>
<td align="right">578</td>
<td align="right">500</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.7</td>
<td>$9.6</td>
<td>$9.6</td>
<td>$255.00</td>
<td>$100.8K</td>
<td align="right">578</td>
<td align="right">60</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$9.2</td>
<td>$8.2</td>
<td>$9.2</td>
<td>$255.00</td>
<td>$45.0K</td>
<td align="right">578</td>
<td align="right">250</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.3</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$255.00</td>
<td>$42.9K</td>
<td align="right">578</td>
<td align="right">355</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$23.4</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$260.00</td>
<td>$41.4K</td>
<td align="right">608</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Having examined the options trading patterns of Danaher, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Danaher</h3>
<ul>
<li>Currently trading with a volume of 1,425,909, the DHR's price is up by 0.36%, now at $251.5. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $280.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Outperform rating for Danaher, targeting a price of $275. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Danaher with a target price of $285. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Danaher options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Danaher Unusual Options Activity

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) and added, &#8220;The long-term growth rate of this thing is fabulous, and I think it's going to <a href="https://www.benzinga.com/quote/BLK/earnings">stay that way.&#8221;</a>
BlackRock, on Jan. 15, reported better-than-expected fourth-quarter financial results. Revenue grew 23% year over year to $5.68 billion, beating the consensus of $5.53 billion.
<h3 class="wp-block-heading">Parabolic Moves In These Stocks</h3>
&#8220;Just great science, but it is parabolic. It had a parabolic move, and those are going to be repealed,&#8221; Cramer said about GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>). He recommended waiting until it gives back a lot of the gain that it just had.
The company's stock rose sharply in the recent period, jumping around 45% year-to-date.
The &#8220;Mad Money&#8221; host recommended waiting until Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) comes down. &#8220;We cannot get involved with a parabolic move of a stock that could go much lower.&#8221;
Supporting his view, Scotiabank analyst Maher Yaghi maintained Digital Realty Trust with a Sector Perform but raised the price target from $178 to $208.
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
&#8220;I think that those guys are great,&#8221; Cramer said when asked about Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>). &#8220;I want them to show me that they understand that there's been some serious underperformance here.&#8221;
Meanwhile, Raymond James analyst Andrew Cooper, on Jan. 21, maintained Danaher with an Outperform rating and lowered the price target from $300 to $275.
Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) is the &#8220;cheapest&#8221; natural gas company, Cramer said.
Supporting his view, Raymond James analyst John Freeman, on Jan. 23, maintained Coterra Energy with an Outperform rating and raised the price target from $35 to $41.
Price Action:
<ul>
<li>Danaher shares gained 2% to settle at $250.59 on Monday.</li>
<li>Coterra shares fell 4.1% to close at $27.83 during the session.</li>
<li>Grail shares dipped 9.2% to settle at $25.99 on Monday.</li>
<li>BlackRock shares rose 0.9% to close at $1,029.94.</li>
<li>Digital Realty shares dipped 8.7% to settle at $164.74 on Monday.</li>
</ul>
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43230206/jim-cramer-is-worried-about-this-consumer-cyclical-stock-7-yield-something-may-be-wrong-here">Jim Cramer Is Worried About This Consumer Cyclical Stock: 7% Yield? &#8216;Something May Be Wrong Here&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

CTRA

GRAL

Jim Cramer Recommends Buying 'Fabulous' BlackRock, Calls Coterra Energy The 'Cheapest' Natural Gas Company

Goldman Sachs expects a gradual recovery in end-market growth throughout the year as the Tools and the contract research organizations (CROs) enter 2025 after underperforming in 2024.
Bioprocessing is anticipated to gain momentum as the year progresses, with instruments poised for recovery by mid-year, potentially achieving healthy growth rates by the fourth quarter. However, investor skepticism remains high following overly optimistic guidance in 2024.
Improved visibility, normalized supply chains, and stable ordering patterns suggest better conditions for 2025, although debates around large pharma spending are expected to dominate early-year discussions.
Goldman Sachs analyst Matthew Sykes is cautiously optimistic about a potential recovery in the Life Sciences Tools sector in 2025. However, investor interest in this area remains low.
The analyst writes that the health care sector saw the fastest pace of net buying in five months last week—except for segments like Life Sciences Tools &amp; Services.
This hesitation stems from repeated disappointments in market recovery, ongoing declines in revenue and earnings forecasts, and persistently high valuations.
Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) and Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) are scheduled to release their fourth-quarter 2024 <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">earnings next week</a>.
Sector allocations among traditional, long-only investors have slightly increased, which is a positive sign.
A BofA Securities&nbsp;report in December highlighted that the Life Sciences Tools sector struggled in <a target="_blank" href="https://www.benzinga.com/24/12/42490115/despite-higher-valuations-some-life-sciences-tools-stocks-create-good-opportunities-analyst" rel="noreferrer noopener">fiscal year 2024</a>.
Pharmaceutical and biotech companies' spending dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed.
For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead to fiscal year 2025, initial forecasts and management comments suggest a mixed outlook.
Over the past two years, hedge funds have driven most of the sector's activity, but their recent pullback, combined with mutual funds' growing interest, could pave the way for broader investor engagement—if the sector demonstrates sustainable recovery.
For this to happen, large biopharma companies, the sector's key customers, need to stabilize spending amid challenges like the Inflation Reduction Act and patent cliffs.
Increased R&amp;D investment would also be crucial. While M&amp;A could support this shift, their net impact is expected to be neutral.
However, M&amp;A activity may still encourage investment to replenish product pipelines for major pharmaceutical companies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43192622/hca-healthcare-q4-earnings-beat-steet-estimates-despite-hurricane-impact-announces-10-billion-share-buyback-program" target="_blank" rel="noreferrer noopener">HCA Healthcare Q4 Earnings Beat Steet Estimates Despite Hurricane Impact, Announces $10 Billion Share Buyback Program</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Analyst Color

Health Care

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery

Raymond James analyst Andrew Cooper maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $300 to $275.

Raymond James Maintains Outperform on Danaher, Lowers Price Target to $275

Citi lowered the firm's price target on Danaher (DHR) to $265 from $285 and keeps a Buy rating on the shares post the Q4 report. The company guided...

Danaher price target lowered to $265 from $285 at Citi

Stifel lowered the firm's price target on Danaher (DHR) to $260 from $265 and keeps a Hold rating on the shares. Danaher being conservative with th...

Danaher price target lowered to $260 from $265 at Stifel

Wells Fargo lowered the firm's price target on Danaher (DHR) to $240 from $280 and keeps an Equal Weight rating on the shares. While Danaher's Biop...

Danaher price target lowered to $240 from $280 at Wells Fargo

Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Danaher (DHR – Research Report) today and set a price target of $260.00. The compa...

Stifel Nicolaus Remains a Hold on Danaher (DHR)

RBC Capital analyst Conor McNamara lowered the firm's price target on Danaher (DHR) to $277 from $299 but keeps an Outperform rating on the shares ...

Danaher price target lowered to $277 from $299 at RBC Capital

TD Cowen analyst Dan Brennan lowered the firm's price target on Danaher (DHR) to $260 from $315 and keeps a Buy rating on the shares. The firm had ...

Danaher price target lowered to $260 from $315 at TD Cowen

Danaher Corporation (($DHR)) has held its Q4 earnings call. Read on for the main highlights of the call. Danaher Corporation's recent earnings call...

Danaher Earnings Call: Mixed Sentiment and Strategic Moves

Leerink Partners analyst Puneet Souda has maintained their bullish stance on DHR stock, giving a Buy rating yesterday. Puneet Souda's rating is bas...

Danaher's Strategic Positioning and Breakthrough in Alzheimer's Diagnostics Market Justifies Buy Rating

In a report released today, Sung Ji Nam from Scotiabank maintained a Hold rating on Danaher (DHR – Research Report), with a price target of $265.00...

Scotiabank Reaffirms Their Hold Rating on Danaher (DHR)

RBC Capital analyst Conor McNamara raised the firm's price target on Thermo Fisher (TMO) to $693 from $689 and keeps an Outperform rating on the sh...

Thermo Fisher price target raised to $693 from $689 at RBC Capital

Press Releases

Danaher to Present at Evercore ISI HealthCONx Conference

Dividends

Danaher Announces Quarterly Dividend

Danaher Schedules Fourth Quarter 2024 Earnings Conference Call

Danaher to Present at J.P. Morgan Healthcare Conference

Danaher Announces Investment Partnership in Innovaccer Inc.

Danaher CEO to Comment on Financial Performance

Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research

Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications

Compass Minerals Announces Senior Leadership Team Appointments

Danaher Reports Fourth Quarter and Full Year 2024 Results

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

Noticias

Últimas noticias sobre Danaher (NYSE:DHR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL